Jemperli combo met its primary endpoint in a trial investigating the drugs in first-line advanced ovarian cancer, but missed ...

LONDON, UK I, 2024 I GSK plc (LSE/NYSE: GSK) today announced headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula ...

UK pharma major GSK today released mixed headline results from the FIRST-ENGOT-OV44 Phase III trial evaluating Zejula ...

GSK (NYSE:GSK) reported mixed results from a Phase 3 study evaluating Zejula, or niraparib, and Jemperli, or dostarlimab, in ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...

(Alliance News) - GSK PLC on Friday said a trial of two ovarian cancer treatments met its primary endpoint but did not meet a key secondary target. The First-Engot-OV44 phase III trial evaluated ...

GSK plc (GSK, GSK.L) reported headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula and Jemperli in first line ...

GSK's combined drugs Jemperli and Zejula met its primary goal of progression-free survival in patients with first line advanced ovarian cancer in a late-stage trial. The British drug maker said that ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

GSK announced positive results from a phase III trial of its ovarian cancer treatment, which met its primary endpoint of progression free survival. Headline results from the FIRST-ENGOT-OV44 phase III ...

GSK has announced positive results from a phase III trial of its ovarian cancer treatment, which met its primary endpoint of ...